Idioma:

Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission

Wei, Andrew H ; Döhner, Hartmut ; Pocock, Christopher ; Montesinos, Pau ; Afanasyev, Boris ; Dombret, Hervé ; Ravandi, Farhad ; Sayar, Hamid ; Jang, Jun-Ho ; Porkka, Kimmo ; Selleslag, Dominik ; Sandhu, Irwindeep ; Turgut, Mehmet ; Giai, Valentina ; Ofran, Yishai ; Kizil Çakar, Merih ; Botelho de Sousa, Aida ; Rybka, Justyna ; Frairia, Chiara ; Borin, Lorenza ; Beltrami, Germana ; Čermák, Jaroslav ; Ossenkoppele, Gert J ; La Torre, Ignazia ; Skikne, Barry ; Kumar, Keshava ; Dong, Qian ; Beach, C.L ; Roboz, Gail J

The New England journal of medicine, 2020-12, Vol.383 (26), p.2526-2537 [Periódico revisado por pares]

United States: Massachusetts Medical Society

Texto completo disponível

Citações Citado por

Enviar para

Título:
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission
Autor: Wei, Andrew H ; Döhner, Hartmut ; Pocock, Christopher ; Montesinos, Pau ; Afanasyev, Boris ; Dombret, Hervé ; Ravandi, Farhad ; Sayar, Hamid ; Jang, Jun-Ho ; Porkka, Kimmo ; Selleslag, Dominik ; Sandhu, Irwindeep ; Turgut, Mehmet ; Giai, Valentina ; Ofran, Yishai ; Kizil Çakar, Merih ; Botelho de Sousa, Aida ; Rybka, Justyna ; Frairia, Chiara ; Borin, Lorenza ; Beltrami, Germana ; Čermák, Jaroslav ; Ossenkoppele, Gert J ; La Torre, Ignazia ; Skikne, Barry ; Kumar, Keshava ; Dong, Qian ; Beach, C.L ; Roboz, Gail J
Assuntos: Acute myeloid leukemia ; Administration, Oral ; Aged ; Aged, 80 and over ; Antimetabolites, Antineoplastic - administration & dosage ; Antimetabolites, Antineoplastic - adverse effects ; Antimetabolites, Antineoplastic - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Azacitidine - administration & dosage ; Azacitidine - adverse effects ; Azacitidine - therapeutic use ; Blood tests ; Bone marrow ; Cancer regression ; Chemotherapy ; Confidence intervals ; DNA methylation ; Double-Blind Method ; Double-blind studies ; Drug Administration Schedule ; Drug therapy ; Female ; Humans ; Leukemia ; Leukemia, Myeloid, Acute - drug therapy ; Leukemia, Myeloid, Acute - mortality ; Maintenance Chemotherapy - adverse effects ; Male ; Middle Aged ; Myeloid leukemia ; Nausea - chemically induced ; Neutropenia ; Quality of Life ; Remission ; Remission (Medicine) ; Remission Induction ; Statistical methods ; Stem cell transplantation ; Survival Analysis ; Thrombocytopenia
É parte de: The New England journal of medicine, 2020-12, Vol.383 (26), p.2526-2537
Descrição: Older patients with acute myeloid leukemia were treated with intensive chemotherapy and then randomly assigned to receive placebo or oral azacitidine (CC-486) daily for 14 days per 28-day cycle. CC-486 was associated with significantly longer relapse-free and overall survival, with some gastrointestinal side effects but maintenance of quality of life.
Editor: United States: Massachusetts Medical Society
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Anterior Resultado 8 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission

United States: Massachusetts Medical Society

Buscando em bases de dados remotas. Favor aguardar.